REMEGEN (09995): Huang Guobin appointed as independent non-executive director.
Rongchang Biology (09995) announced that Mr. Huang Guobin was appointed as an independent director of the second board of directors at the extraordinary general meeting.
REMEGEN (09995) announced that Mr. Huang Guobin has been appointed as an independent non-executive director of the second board of directors at the temporary shareholders' meeting. Mr. Huang's appointment is effective immediately after the temporary shareholders' meeting and will continue until the end of the second term of the board of directors. Mr. Huang has also been appointed as the chairman of the nomination committee and a member of the strategic committee, effective from his appointment as an independent non-executive director at the temporary shareholders' meeting until the end of the second term of the board of directors.
After the temporary shareholders' meeting, Dr. Ma Lan will no longer serve as an independent non-executive director, chairman of the nomination committee, and member of the strategic committee.
Related Articles

Caitong: The adjustment in the liquor industry is nearing completion, with leading management continuing to increase market share.

HK Stock Market Move | BILIBILI-W(09626) rose by over 9%, recent new game performance impressive, the company's commercial value expected to gradually release.

HK Stock Market Move | CSTONE PHARMA-B(02616) rose over 7% in early trading. The company presented the phase I clinical trial data of CS2009 for the first time at the 2025 ESMO Annual Meeting.
Caitong: The adjustment in the liquor industry is nearing completion, with leading management continuing to increase market share.

HK Stock Market Move | BILIBILI-W(09626) rose by over 9%, recent new game performance impressive, the company's commercial value expected to gradually release.

HK Stock Market Move | CSTONE PHARMA-B(02616) rose over 7% in early trading. The company presented the phase I clinical trial data of CS2009 for the first time at the 2025 ESMO Annual Meeting.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025